Breastfeeding warning
Use during breastfeeding only on medical advice.
Medicine information RYBELSUS 14mg tablets
- Product code:
- W66743003
- Quantity:
- 90
- Indicated for:
- type 2 diabetes mellitus; weight management
- Route of administration:
- oral
- Substance:
- semaglutide (GLP-1 receptor agonist)
- ATC
- A10BJ06 — Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Glucagon-like peptide-1 (GLP-1) analogues
Semaglutide is a medication used to treat type 2 diabetes and, in some cases, to manage body weight in patients with obesity or overweight. It belongs to the class of GLP-1 receptor agonists (glucagon-like peptide-1), which work by stimulating insulin secretion, reducing glucagon secretion, and slowing gastric emptying, thereby lowering blood sugar levels and reducing appetite.
Semaglutide is available as a subcutaneous injection (administered once weekly) or, in some cases, as oral tablets. It is used in combination with a healthy diet and exercise to improve glycemic control and, in the case of obesity treatment, to support weight loss.
Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, especially at the start of treatment. In rare cases, it may cause pancreatitis, hypoglycemia (particularly when used with other antidiabetic medications), or thyroid problems.
Semaglutide is not recommended for patients with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2). It is important for patients to follow their doctor's recommendations and monitor for any adverse reactions.
Semaglutide is available as a subcutaneous injection (administered once weekly) or, in some cases, as oral tablets. It is used in combination with a healthy diet and exercise to improve glycemic control and, in the case of obesity treatment, to support weight loss.
Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, especially at the start of treatment. In rare cases, it may cause pancreatitis, hypoglycemia (particularly when used with other antidiabetic medications), or thyroid problems.
Semaglutide is not recommended for patients with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2). It is important for patients to follow their doctor's recommendations and monitor for any adverse reactions.
General data about RYBELSUS 14mg
- Substance:
- semaglutide
- Date of latest medicines list:
- 01-10-2026
- Product code:
- W66743003
- Strength:
- 14mg
- Pharmaceutical form:
- tablets
- Quantity:
- 90
- Product type:
- Original
- Price:
- 1380.38 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for semaglutide
Strengths available for semaglutide
- 0.25mg
- 0.5mg
- 1.34mg/ml
- 1.5mg
- 1.7mg
- 14mg
- 1mg
- 2.4mg
- 2.68mg/ml
- 25mg
- 3mg
- 4mg
- 7.2mg
- 7mg
- 9mg
Official documents
The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.
The correspondence between the document and the displayed text is unconfirmed.
- Source institution
- EMA
- Document language
- English
- Source record: first published
- 27/05/2020
- Source record: last updated
- 22/04/2026
Warnings:
Pregnancy warning
Use during pregnancy only on medical advice.